MarketCap
Facebook
X
TelegramAnnual report 2024
added 05-07-2025
Axon Enterprise DPO Ratio 2011-2026 | AXON
Annual DPO Ratio Axon Enterprise
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.9 | 138 | 36.5 | 31.9 | 34.5 | 42.2 | 34.3 | 22.9 | 40.1 | 38.7 | 44.5 | 43.7 | 48.3 | 36.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 138 | 22.9 | 44.4 |
Quarterly DPO Ratio Axon Enterprise
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.5 | - | - | 47 | 44.5 | 41.3 | - | 23.4 | 45 | 37 | - | 18.4 | 15.6 | 28 | - | 32.3 | 41.5 | 39 | - | 46.6 | 50.5 | 39.9 | - | 35.3 | 38.4 | 29.5 | - | 19.4 | 23.1 | 28.8 | - | 38.7 | 45.7 | 44.3 | - | 34.7 | 41.9 | 46 | - | 44.8 | 50.2 | 45.4 | - | 43.3 | 45.7 | 47.4 | - | 47.4 | 48.5 | 47.1 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50.5 | 15.6 | 38.6 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
-556 | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Axsome Therapeutics
AXSM
|
529 | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
245 | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Compugen Ltd.
CGEN
|
82.7 | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Coherus BioSciences
CHRS
|
507 | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Clovis Oncology
CLVS
|
236 | - | -7.23 % | $ 13 M | USA |
 |
Curis
CRIS
|
3.24 K | $ 0.77 | 1.89 % | $ 4.86 M | USA |